APA (7th ed.) Citation

R, P., I, B., RA, F., AY, K., JM, K., MB, G., . . . AG, M. (2022). Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Frontiers in endocrinology, 13, 899616. https://doi.org/10.3389/fendo.2022.899616

Chicago Style (17th ed.) Citation

R, Pivonello, et al. "Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study." Frontiers in Endocrinology 13 (2022): 899616. https://doi.org/10.3389/fendo.2022.899616.

MLA (9th ed.) Citation

R, Pivonello, et al. "Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study." Frontiers in Endocrinology, vol. 13, 2022, p. 899616, https://doi.org/10.3389/fendo.2022.899616.